BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-05 17:05 |
BioLineRx Announces Oral Presentation at ASH 2024
|
English | 36.5 KB | ||
| 2024-10-16 17:53 |
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on
Moti…
|
English | 1.6 MB | ||
| 2024-10-16 17:53 |
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on
Moti…
|
English | 36.3 KB | ||
| 2024-10-06 12:45 |
Results of the Company’s Annual General Meeting of Shareholders which was held …
|
English | 62.3 KB | ||
| 2024-10-06 12:45 |
Results of the Company’s Annual General Meeting of Shareholders which was held …
|
English | 36.3 KB | ||
| 2024-08-20 01:39 |
Immediate Report of Meeting to be held on October 1, 2024,proxy statement
|
English | 62.4 KB | ||
| 2024-08-20 01:39 |
Immediate Report of Meeting to be held on October 1, 2024,proxy statement
|
English | 187.1 KB | ||
| 2024-08-20 01:39 |
Immediate Report of Meeting to be held on October 1, 2024,proxy statement
|
English | 110.8 KB | ||
| 2024-08-15 16:05 |
Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
|
English | 475.6 KB | ||
| 2024-08-15 16:05 |
Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
|
English | 36.4 KB | ||
| 2024-06-19 01:09 |
FORM 6-K-A complaint was filed with the District Court of Jerusalem
|
English | 61.2 KB | ||
| 2024-06-19 01:09 |
FORM 6-K-A complaint was filed with the District Court of Jerusalem
|
English | 36.3 KB | ||
| 2024-05-30 16:05 |
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research …
|
English | 526.2 KB | ||
| 2024-05-30 16:05 |
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research …
|
English | 36.6 KB | ||
| 2024-05-28 16:05 |
Reports First Quarter 2024 Financial Results and Recent Corporate
and Portfolio…
|
English | 534.3 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
